Immunefi: The average loss per single attack in the crypto industry is about $24.5 million
Foresight News reports that according to Immunefi's 2026 On-chain Security Report, there were a total of 191 publicly disclosed attack incidents between 2024 and 2025, with total losses reaching $4.67 billions. Over five years, cumulative losses amounted to $11.9 billions, involving 425 attacks. In 2024, 94 attacks were recorded, and in 2025, 97 attacks occurred, with the overall frequency stabilizing.
The median loss per attack dropped from the previous $4.5 million to about $2.2 million, but the average loss remained as high as approximately $24.5 million. The five largest incidents between 2024 and 2025 accounted for 62% of the total stolen funds, while the top ten accounted for 73%. Among them, a single $1.5 billions attack on an exchange represented 44% of all losses in 2025 and 32% of the total losses over the two years.
Although centralized exchanges were involved in only 20 out of the 191 incidents, they bore more than half of the total losses, amounting to $2.55 billions. The tokens of attacked projects dropped by an average of about 10% within two days after the incident, and the median decline reached 61% after six months. About 84% of affected tokens remained below their pre-attack levels six months later.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
